New Study Evaluating BPA Use With Emicizumab Among Patients With Hemophilia A
Researchers are seeking to evaluate outcomes after initiation of emicizumab and concomitant BPAs in patients with hemophilia A and FVIII inhibitors.
Researchers are seeking to evaluate outcomes after initiation of emicizumab and concomitant BPAs in patients with hemophilia A and FVIII inhibitors.
Researchers sought to determine whether emicizumab would be safe and effective in pediatric patients with hemophilia A with FVIII inhibitors.
Researchers sought to determine whether rVIII-SingleChain therapy would be safe and effective as a long-term prophylaxis option for previously treated patients with hemophilia A.
Researchers sought to revise the GOAL-Hēm patient-reported outcomes tool to be more patient-centric for patients with hemophilia.
Researchers sought to determine whether efanesoctocog alfa may yield high sustained FVIII activity and improve bleed protection in patients with severe hemophilia A.
In open-label study, substantial increase seen in factor VIII activity at weeks 49 to 52 of follow-up.
In preclinical studies, ASC618 has been shown to have at least a 10-fold increase in the biosynthesis and secretion of FVIII compared with native human FVIII bioengineered constructs.
Researchers sought to determine the incidence of fatal and nonfatal CVD during 5 years of follow up in adults with hemophilia.
Researchers sought to determine the attitudes and expectations of patients with hemophilia belonging to Generation Y regarding their treatment.
Researchers sought to provide perspectives and recommendations for engaging patients with hemophilia in physical activity.